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ABSTRACT: The valency of quantum dot nanoparticles conju-
gated with biomolecules is closely related to their performance
in cell tagging, tracking, and imaging experiments. Commer-
ciallyavailablestreptavidinconjugates(SAvQDs)arethemost
commonly used tool for preparing QD-biomolecule conju-
gates.Theﬂuorescencequenchingofbiotin-4-ﬂuorscein(B4F)
provides a straightforward assay to quantify the number of
biotinbindingsitesperSAvQD.Theutilityofthismethod was
demonstrated by quantitatively characterizing the biotin bind-
ing capacity of commercially available amphiphilic poly(acrylic
acid) Qdot ITK SAv conjugates and poly(ethylene glycol)
modiﬁedQdotPEGSAvconjugateswithemissionwavelengths
of 525, 545, 565, 585, 605, 625, 655, 705, and 800 nm. Results showed that 5- to 30-fold more biotin binding sites are available on
ITK SAv QDs compared to PEG SAv QDs of the same color with no systematic variation of biotin binding capacity with size.
’INTRODUCTION
QDs are semiconductor nanoparticles that have size and
composition tunable ﬂuorescence emission spectra, narrow emission
bands, and very high levels of brightness and photostability.
1-3In the
12yearssincequantumdots(QDs) wereﬁrstrenderedbiochemically
stableforbiologicalapplications,
4,5manygroupshavebeenworkingto
optimizeorapplyQDconjugatestoanswerbiological,biomedical,and
clinical research questions.
5-20 A wide number of approaches have
been used to chemically modify QDs with biomolecules and to apply
them to a range of assays and imaging methods.
4,5,7,9,12,15,16,21-23 The
most practical bioconjugation method to emerge makes use of the
high-aﬃnity and selective interaction of biotinylated ligands with
commercially available SAv QD conjugates. For example, SAv QDs
canbeusedtoperformmulticoloranalysisofmultipleantigen-speciﬁc
cell populations in ﬂow cytometry. By creating QD conjugates or
MHC tetramers targeted toward a variety of cell surface proteins, one
can reveal phenotypic characteristics important in understanding cell
diﬀerentiation and immune responses.
24 Others have used SAv QDs
conjugated to biotin-modiﬁed proteins of interest to target and image
cellularstructuressuchasmembranereceptors,actin,nuclearantigens,
or DNA.
9,14-16,19,20,25-27
As colloidal materials, synthesized QD conjugates are known
to vary in physiochemical and biochemical properties. This
variationhas resultedindiﬀerencesincellularuptake,subcellular
localization, and systemic distribution of QDs bearing diﬀerent
surfacecharacteristicsinvivo.
28Sincetheyarecolloidalmaterials,
QDs tend to have multiple biological ligands linked on a single
particle. Hence, QDs have biophysical and biological properties
that are distinct from typical dye conjugates. For many biophy-
sical and cell biology studies, stoichiometry must be adjusted to
avoid multivalency issues such as receptor cross-linking. How-
ever, published methods for quantifying bioactivity of QD
conjugates are material intensive or rely on special equipment.
Ligand density is known to aﬀect cell internalization of
recognized substrates,
29 and variations in QD valency can aﬀect
cross-linking of surface proteins, activating signaling pathways
and reducing receptor mobility.
18,20,30,31 Such variation in QD
bioactivity makes protocols unreliable and questions dependent
on the binding capacity of QDs diﬃcult to answer. For example,
Wu et al. were unable to use biotin beads to develop ﬂow
cytometry calibration standards because the valency of SAv
QDs was unregulated, as witnessed by inconsistent ﬂow cyto-
metry readings.
32 In addition, variable valency can aﬀect the
quantitation of ﬂuorescent binding experiments.
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Conjugate valency is an essential parameter to determine for
any conjugate, yet there are few reports and even fewer methods
published for routine characterization of QD valency. Using an
isotopedilutionmethod,Caietal.quantiﬁedthenumberofRGD
peptidesperQDparticle.
1Clarkeetal.developedaradiolabeling
assay to track the attachment of small biomolecules to QD
surfaces.
33 Swift et al. determined the number of biotin binding sites
perSAvQDusingbiotinylatedQDsinablockingbindingassaywith
two-photon excitation ﬂuorescence cross-correlation spectroscopy
(TPE-XCS) analysis.
34 Additional methods using chromatographic
or electrophoretic techniques, gel electrophoresis, and AFM qualita-
tively address questions of QD size, morphology, and mobility
related to valency.
17,18,28,30,35-38 It is essential to quantify the bioac-
tivity of each preparation of QD conjugates, to account for non-
uniformitiesinsize,surfacechemistry,andcouplingeﬃciency.
39This
is sine qua non for dye conjugates and represents a signiﬁcant short-
coming in the literature of QD conjugates. The ability to correlate
QD valency with bioactivity and performance will allow determina-
tion of the optimum number of bioligands required for eﬃcient
conjugate preparation or delivery into cells
12,26 and may provide a
quantitative basis for variations seen in both commercially available
and homemade QDs.
Our group previously developed a method to code mamma-
liancellswithQDsutilizingcommerciallyavailableSAvQDsand
biotinylated polyarginine (polyarg) peptide.
36 In this past work,
the half-saturation of polyarg conjugated QD (polyarg QD)
uptake by Swiss 3T3 mouse ﬁbroblast cells was reached at 27-
fold molar excess of polyarg to SAv QD. While loosely related to
valency of the QDs under study, this phenomenological value is
dependent on experimental conditions and cell type and not a
directmeasurement ofthenanoparticle valency. Currently,there
is no clear or practical method by which researchers can
determine a quantitative value for the binding capacity of SAv
QDs for biotinylated ligands. Researchers rely on rough esti-
matesof valency based on startingmaterial concentrations inthe
conjugation reaction, rough estimates based on mobility assays,
or rough estimates as provided by the manufacturer. Traditional
methods of absorbance ratios or HABA ﬁltrations are of limited
utility duetothe largeUV absorbance cross-section of QDs.The
literature reports a wide range of values for either the number of
SAv per QD or number of biotin binding sites per QD as shown
in Table 1. The goal of this study was to develop a rapid,
straightforward, and quantitative method that utilizes minimal
QD stock material to directly measure the biotin binding
capacities of SAv QDs.
Our approach was to apply a biotin-4-ﬂuorescein (B4F)
quenching titration assay to QDs to characterize the number of
biotin binding sites per QD. B4F is a commercially available dye,
which quenches upon binding to SAv.
40-45 The number of
biotin-binding sites is determined by the point of intersection
between two binding regimes in a titration of the conjugate with
B4F.
40-43,46Theﬁrstregimeofﬂuorescencequenchingoccursat
lower concentrations of B4F ligand relative to conjugate con-
centration. Here, B4F molecules are quantitatively bound by the
available biotin binding sites. There is some nonlinearity in this
regime due to the fact that the extent of B4F ﬂuorescence
quenching varies with the number of B4F molecules bound per
substrate molecule.
40 The most pronounced quenching occurs
when all four sites of the SAv are bound with B4F. In a 4-to-1
B4F-to-SAv complex, the extent of B4F ﬂuorescence quenching
by SAv is 88%.
40 After the saturation point, a second linear
regimeofconcentration-dependentﬂuorescenceoccursathigher
concentrations of B4F ligand to substrate concentration. This
ﬂuorescence assay detects down to 0.5 nM binding sites in
puriﬁed proteins with 30 min incubation conditions.
40 This
method provides a direct measurement of availablebinding sites,
rather than the number of conjugated proteins. Where questions
of ligand stoichiometry are important, this technique gives a
more accurate, quantitative description of biochemical valency
comparedtosizeorchargedependentanalyses.Thismethodwas
applied to a range of commercial SAv functionalized QDs.
’EXPERIMENTAL PROCEDURES
CalibrationofB4FConcentration. Theestimatedor“nominal”
concentrationofB4Fwasdeterminedfrommeasuredabsorbanceof
B4F(Invitrogen) at495nmobtainedbyUV-visspectroscopyona
PerkinElmer Lambda 45 instrument, based on an extinction coeffi-
cient of 68000 M
-1 cm
-1.
40,43,44 Kada et al. note uncertainty
associated with this molar extinction coefficient, which can be
calibrated for effective concentration of B4F using a known amount
ofsubstratewithcertainextinctioncoefficientandnumberofbinding
sites.
40,42,46 In this case, we used SAv to calibrate B4F concentra-
tionbecauseitiswell-knowntohave4biotinbindingsitespermole-
cule.
47 The concentration of SAv (Sigma) was determined from
measuredabsorbanceofSAvat280nmwithanextinctioncoefficient
of204000M
-1cm
-1asprovidedbythemanufacturer.
471nMSAv
was titrated with a 2-fold serial dilution of B4F in terms of nominal
concentration as described in thea s s a yb e l o w .S i n c et h e r ea r e4
bindingsitesperSAvmolecule,theintersectionpointofthetitration
marking saturation of all binding sites per SAv should occur at 4 nM
B4F. Therefore, the value of the intersection point, in terms of
nominal concentration, is divided by 4 to obtain a correction factor
for effective concentration. Then, values of biotin binding site per
particle, in terms of nominal concentration, are divided by the
correction factor to obtain the number of biotin binding sites per
particle, in terms of effective concentration.
B4F Fluorescence Binding Assay of SAv and SAv QDs. In
black-walled, flat, clear-bottomed 96 well plates (CoStar), 1 nM
(QD concentrations as provided by manufacturer) poly-
(ethylene glycol) (PEG) SAv QDs (Invitrogen) with emission
wavelengths (nm) of 525 (Qdot SAv conjugate Q10141MP),
565 (Qdot SAv conjugate Q10131MP), 585 (Qdot SAv con-
jugateQ10111MP),605(QdotSAvconjugateQ10101MP),625
(Qdot SAv conjugate A10196), 655 (Qdot SAv conjugate
Q10121MP), 705 (Qdot SAv conjugate Q10161MP), and 800
(Qdot SAv conjugate Q10171MP); poly(acrylic acid) amphilic
Table 1. Summary of Literature Reports of Binding Capacity
of SAv QDs
30,32,48,50,53-56
no. of SAv per QD
no. of biotin binding
sites per QD source
4 to 10 16 to 40 Howarth, 2008
5 to 10 15 to 30 Young, 2005
5 to 10 - Vu, 2005
5 to 10 - Lidke, 2007
6 to 8 2 to 3 Invitrogen, 2006
8 to 10 - Wu, 2007
- 10 Swift, 2006
10 - Carstairs, 2009
15 to 25 - Zhang, 2005
- 20 Ruan, 2007364 dx.doi.org/10.1021/bc100321c |Bioconjugate Chem. 2011, 22, 362–368
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(AMP) SAv QDs (Invitrogen) with emission wavelengths (nm)
of 525 (Qdot ITK SAv conjugate Q10041MP), 545 (Qdot ITK
SAv conjugate Q10091MP), 565 (Qdot ITK SAv conjugate
Q10031MP), 585 (Qdot ITK SAv conjugate Q10011MP),
605 (Qdot ITK SAv conjugate Q10001MP), 625 (Qtracker
Cell Labeling Kit: Component A A10198), 655 (Qdot ITK
SAv conjugate Q10021MP), 705 (Qdot ITK SAv conjugate
Q10061MP), and 800 (Qdot ITK SAv conjugate Q10071MP);
and SAv were titrated in triplicate independent series with a
2-fold serial dilution of nominal 500 nM to 0.488 nM and 0 nM
B4F in filtered 0.05 M Tris buffered saline (TBS) pH 8.0
(Sigma). This titration is therefore a noncumulative titration of
QDs or SAv. A row of the serial dilution of B4F alone was
included as a positive signal control. Samples were incubated for
one hour at room temperature in the dark. As a control for
specificity between SAv and the biotinylated dye, 525 ITK SAv
QDs (Qdot ITK SAv conjugate Q10041MP) and SAv were
blocked with 10 μM biotin for 30 min and titrated with B4F as
described. Carboxyl QDs (Qdot 705 ITK carboxyl Q21361MP)
were also titrated under the same conditions asa control forzero
biotin binding sites of unfunctionalized QDs. Using a Tecan
Safire2 fluorescence plate reader, wells were measured for
fluorescence at 525 nm with excitation at 490 nm and gauging
gainoffofthehighest525nmfluorescencesignal:500nMbiotin-
4-fluorescein without QDs or SAv.
Filtration of B4F Dye. PEG and ITK SAv 525 and 705 QDs,
SAv, and B4F alone were assayed as described above. Afterward,
samples were transferred to 10000 or 30000 MW cutoff filter
plates (Millipore or Pall, respectively) and centrifuged at 3000 g
for 1 h or 10 min, respectively. Eluent was transferred to optical
well plates and analyzed using a Tecan Safire2 fluorescence plate
reader for fluorescence at 525 nm with excitation at 490 nm and
gauging gain off of the highest 525 nm fluorescence signal: 500
nM biotin-4-fluorescein without QDs or SAv.
Data and Statistical Analysis. Background fluorescence
signal at 0 nM B4F for SAv and SAv QDs was subtracted from
signal at 500 nM to 0.488 nM B4F. The signal for each species
wasplottedagainstB4Fnominalconcentration.UsingGraphPad
Prismsoftware,thelinearregimeofeachserieswasdefinedbythe
points that fell on a linear regression by robust R
2 value (closest
to 1.0) and inspection. Since fluorescence is linear with dye
concentration, we can be certain about the points that fit a linear
regression. The first outlier of the linear regression was used to
definetheendofthenonlinearregime.Thenonlinearregimewas
fit to a second-order polynomial; the nonlinearity is the result of
stronger fluorescence quenching of B4F when 3-4 versus 1-2
biotin binding sites per SAv molecule are occupied.
40,43 The
intersection point of the titration was determined by solving for
the positive root of the polynomial generated from the equiva-
lence of the two-fit function using Matlab software. The x-value
of the root represents the number of biotin sites per particle.
Standard deviations of the roots of the polynomial were calcu-
latedusingMatlabfromthestandarddeviationofthecoefficients
of the polynomial and linear fits. The numbers of biotin binding
sites were converted from terms of nominal concentration to
terms of effective concentration of B4F by dividing by the
correction factor obtained in the calibration of B4F concentra-
tion with SAv as described in Calibration of B4F Concentration.
While graphical analysis was conducted in linear scale, titration
profiles were plotted in log-log scale for presentation.
’RESULTS
The approach described in this paper is a quick, simple assay
relying on small volumes of stock QD material (4-10 μL given
stock at 1-2 μM) that can be used routinely to characterize the
Figure 1. Eﬀective biotin binding capacity per particle by B4F ﬂuorescence quenching assay. (A) PEG SAv QDS, (B) ITK SAv QDs. Error bars
represent standard deviation of the mean of independent triplicate samples.
Table 2. Number of Biotin Binding Sites per SAv QD
number of biotin binding sites
PEG SAv QDs ITK SAv QDs
emission
wavelength (nm) value (SD) cat no value (SD) cat no
525 4(1) Q10141MP 41(12) Q10041MP
545 NA NA 63(8) Q10091MP
565 3(1) Q10131MP 62(8) Q10031MP
585 5(1) Q10111MP 83(16) Q10011MP
605 2(1) Q10101MP 60(7) Q10001MP
625 5(1) A10196 61(6) A10198
655 5(1) Q10121MP 67(10) Q10021MP
705 5(1) Q10161MP 72(13) Q10061MP
800 12(1) Q10171MP 79(24) Q10071MP365 dx.doi.org/10.1021/bc100321c |Bioconjugate Chem. 2011, 22, 362–368
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number of biotin binding sites on QDs. This ﬂuorescence-quench-
ing assay revealed signiﬁcant quantitative diﬀerences in biotin
binding capacity of commercially available SAv QDs (Invitrogen,
Corp, Carlsbad, CA). The average number of biotin binding sites
per batch of PEG SAv QDs and ITK SAv QDs studied in this work
are illustrated in Figure 1 and listed in Table 2. These analyses were
conducted on new QD samples, as supplied by the manufacturer,
assumingstockmaterialsarefreeofimpuritiesorunconjugatedSAv.
Ifanalyseswillbeconductedonoldersamples,thenultraﬁltrationof
QD materials prior to titration with B4F would eliminate any free
SAv due to degradation from analysis.
Representative titration proﬁles of PEG versus ITK SAv 705
QDs are shown in Figure 2. To prove the quantitative and
accurate nature of this assay despite potential FRET eﬀects or
overlap of emission wavelengths between B4F emission and 525
QDs, samples of PEG and ITK SAv QDs with 525 and 705 nm
emission wavelengths were measured before and after ultraﬁltra-
tion (30 kDa) of unbound B4F dye to determine the number of
biotin binding sites per particle as shown in Figure 3.
The nominal concentration of B4F in this study was close to
the eﬀective concentration derived by titration of a known
concentration of free SAv protein (see Supporting Information
Figure S1). It is well-known that free SAv has 4 biotin binding
sites per molecule.
47 As a result, the factor by which all QD
species’ nominal binding capacity values were divided by in this
work was 1.384.
Unconjugated QDs (Supporting Information Figure S2) and
biotinblockedQDs(SupportingInformationFigureS3)showed
no signature of binding or nonlinearity, thus lacking any measur-
able biotin binding capacity, and conﬁrming the speciﬁcity of the
quenching for the biotin-SAv interaction.
Kadaetal.haveshownthatthisassayisaccurateandreproducible
down to 0.5 nM SAv with 30 min incubation.
40 Nevertheless, an
incubation time study was conducted which conﬁrmed that this
assay was accurate at 1 nM SAv with 1 h incubation (Supporting
Information Figure S4) and reproducible (compare to Supporting
Information Figure S4 to Figure S1).
’DISCUSSION
The biotin binding sites per QD determined by the B4F
method as shown in Table 2 are more instructive than the rough
estimates reported by the literature and commercial sources as
listed in Table 1. Invitrogen notes that any values they provide
are indeed only estimates, dependent on batch, emission wave-
length,andsterichindrance ofbound SAv.
48However,assuming
estimates of SAv QD valency has been insuﬃcient for a number
of research applications.
34,39,49,50 It should be noted that the
biotin binding values determined here represent the number of
biotin binding sites available to B4F and other molecules with
similar steric hindrance characteristics. Therefore, these values
may not translate to the number of biotin binding sites available
tolargerbiotinylatedmolecules.Nonetheless,ourmethodallows
for a standard approach for batch-speciﬁc characterization of the
number of biotin binding sites per QD.
It is clear from Table 2 that there are signiﬁcantly more biotin
binding sites available on ITK SAv QDs compared to PEG
SAv QDs. PEG SAv QDs (the regular Qdot SAv conjugates
from Invitrogen) utilize a PEG linker chemistry to ensure
high-quality staining and low background levels under phy-
siological conditions, whereas ITK SAv QDs have SAv cova-
lently attached to the inner amphiphilic coating without
the PEG linker for applications such as ﬂuorescence reso-
nance energy transfer (FRET).
51 Clearly, the PEG linker
chemistry results in a signiﬁcantly lower average number of
biotin binding sites. Therefore, it is important to understand
which type of SAv QD—PEG modiﬁed or unmodiﬁed—one
has purchased when biotin binding capacity plays a large role
in results, as it would in many QD functionalization and
labeling experiments.
Figure2. Representativetitrationproﬁlesof1nMPEGSAvandITKSAv705QDswithB4F.(A)Log-logplotof1nMPEGSAv705QD(QdotSAv
conjugate Q10161MP) titrated with B4F. (B)Log-log plotof 1 nMITK SAv 705 QD (Qdot ITK SAv conjugate Q10061MP) titrated with B4F.Both
titrationsresultedintworegimesofﬂuorescencebehavior:theﬁrstregimeatlowconcentrationsofB4Fﬁttoasecond-orderpolynomialandthesecond
regime at high concentrations of B4F ﬁt to a linear regression. Error bars represent the standard deviation of the mean of independent triplicate series.
Figure 3. Number of biotin binding sites per particle before and after
ﬁlterseparationoffreeB4Ffromparticles.Errorbarsrepresentstandard
deviation of the mean of independent triplicate samples.366 dx.doi.org/10.1021/bc100321c |Bioconjugate Chem. 2011, 22, 362–368
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Figure 3 shows that emission of 525 QDs does not interfere
with the accuracy of the B4F titration signal. Notably, B4F
ﬂuorescence properties for the purpose of this assay in ITK
SAv QDs—where the PEG linker chemistry is omitted—are not
aﬀected by FRET eﬀects due to proximity with QDs. Since
results were altered by neither ﬁltration nor the removal of QD-
bound B4F, there is no interference from the QD absorbance or
emission in these results. Filtration is therefore unnecessary, and
this assay can be done as a simple “mix-and-read” ﬂuorescence
titration.
Invitrogen estimates that QDs of greater size, a characteristic
dependentoncorecompositionandemissionwavelength,willhave
a higher number of SAv ligands.
48 However, our results show that
this mnemonic is neither consistently nor anecdotally true in an
arrayofcommercialsamples.Someintermediate-sizedQDs,suchas
the 605-nm-emitting PEG SAv QD and the 585-nm-emitting ITK
SAv QD samples, exhibited signiﬁcantly lower or higher binding
capacity compared to larger or smaller QDs as shown in Figure 1
and Table 2. These results underscore the need for a batch-speciﬁc
characterization method such as the one developed here.
Theﬂuorescence-bindingassaydescribedhereenablesparallel
analysis of many samples at one time with minimal sample
consumption. According to Invitrogen, the most accurate meth-
od for general detection of extent of functionalization on QDs is
bysizeexclusionchromatography,wheremorehighlyconjugated
QDs would have a longer retention time than less conjugated
QDs.
48Ourlab,as wellasotherlaboratories, previously reported
using gel electrophoresis to determine the extent of conjugation
of a given batch of QD conjugates.
17,18,28,30,35-38,52 However,
these methods are material and time intensive and infer con-
jugation from size rather than directly measuring bioactivity.
Lastly, the multiplate assay format requires smaller sample
volumes, consuming <4% of the commercially provided material
for a triplicate analysis of the biotin binding capacity.
The B4F titration method described and applied in this paper
has demonstrated signiﬁcant variance in biotin binding capacity
of commercial QDs of diﬀerent surface chemistry and emission
color. Quantitative characterization of the binding capacity of
commercially available amphiphilic polymer stabilized SAv QDs
(Qdot ITK SAv conjugate) and poly(ethylene glycol) functional
SAv QDs (Qdot SAv conjugate) with emission wavelengths of
525, 545, 565, 585, 605, 625, 655, 705, and 800 nm demonstrated
that signiﬁcantly more biotin binding sites are available on ITK
SAv QDs compared to PEG SAv QDs. The number of biotin
binding sites per SAv QD does not necessarily increase with QD
size across a series of QD colors. Importantly, this assay gives
quantitative and accurate information without interference from
FRET eﬀects or ﬂuorescence emission overlap with B4F. Mea-
surements using this method give accurate values of SAv QD
biotin binding capacity and could be used as a tool to benchmark
shelf stability and functionalization chemistry of QD SAv con-
jugates.Thisinformationandthereportedmethodologyshouldbe
standard practice for characterization of QD SAv conjugates prior
to further conjugation.
’ASSOCIATED CONTENT
b S Supporting Information. Figures S1-S4 provide repre-
sentative curves of B4F concentration calibration, control titra-
tions, and incubation time comparisons for the B4F eﬀective
concentration determination. This material is available free of
charge via the Internet at http://pubs.acs.org.
’AUTHOR INFORMATION
Corresponding Author
*Corresponding author. E-mail: bruchez@cmu.edu. Mail: 4400
Fifth Avenue, Pittsburgh, PA 15213. Phone: 412.268.9661. Fax:
412.268.6571.
’ACKNOWLEDGMENT
R.M. was supported by a Dowd-ICES Fellowship. M.P.B. is
supported by the NIH National Technology Centers for Net-
works and Pathways (TCNP) U54-RR022241. This work was
initiallysupportedbytheNIHBioengineering ResearchPartner-
ship (BRP) program (5R01-EB000364). We acknowledge Eric
Tulsky and Kari Haley at Invitrogen Corp. for QD samples and
Professor Phil Campbell for useful discussions.
’NOMENCLATURE
B4F Biotin-4-ﬂuorescein
SAv QD Streptavidin quantum dot conjugate
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